1. Home
  2. PRSO vs LNAI Comparison

PRSO vs LNAI Comparison

Compare PRSO & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$0.78

Market Cap

13.4M

Sector

Technology

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

HOLD

Current Price

$3.21

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
LNAI
Founded
2008
N/A
Country
United States
United States
Employees
N/A
29
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
11.8M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
PRSO
LNAI
Price
$0.78
$3.21
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
602.0K
674.9K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
81.23
N/A
EPS
N/A
N/A
Revenue
$14,573,000.00
N/A
Revenue This Year
$18.48
N/A
Revenue Next Year
$53.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.99
N/A
52 Week Low
$0.77
$0.15
52 Week High
$2.37
$5.02

Technical Indicators

Market Signals
Indicator
PRSO
LNAI
Relative Strength Index (RSI) 33.69 57.09
Support Level N/A $0.57
Resistance Level $0.95 $3.38
Average True Range (ATR) 0.05 0.59
MACD -0.02 -0.02
Stochastic Oscillator 10.71 33.54

Price Performance

Historical Comparison
PRSO
LNAI

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: